Contraceptives Market Outlook:
Contraceptives Market size was valued at USD 35.4 billion in 2026 and is expected to reach USD 65.7 billion by the end of 2036, registering around 6.4% CAGR during the forecast period, i.e., between 2027-2036. In 2027, the industry size of contraceptives is estimated at USD 37.6 billion.
The global contraceptives market is expected to witness surging growth, which is supported by a large and diverse patient population of women and couples who are looking for birth spacing or pregnancy prevention. Market growth is primarily being driven by increasing awareness of reproductive health and greater emphasis on reproductive autonomy. In July 2025, the World Health Organization stated that around 1.9 billion women aged 15 - 49 worldwide were of reproductive age, and 1.1 billion needed family planning services. It also stated that of these, 874 million were using modern contraceptive methods, whereas 164 million had an unmet need for contraception. In addition, the WHO projects that about 70 million additional women could gain access to contraception by 2030, thus supporting healthier market growth.
Furthermore, payers are an important market force, wherein governments, public-health programs, private insurers, employers, and out-of-pocket consumers influence product uptake through reimbursement, formularies, subsidies, and affordability initiatives. In this context, the Commonwealth Fund in July 2025 stated that U.S. public policy, particularly the Affordable Care Act, has significantly improved contraceptive affordability by requiring many private insurance plans to cover FDA-approved methods without cost sharing. It also outlined that exemptions, state-level differences, insurance formularies, and limited coverage of over-the-counter and male contraceptives create gaps in access and affordability. Therefore, expanding state and federal protections has the potential to help ensure more consistent, affordable access to a wider range of options benefiting the overall contraceptives market.
Key Contraceptives Market Insights Summary:
Regional Highlights:
- North America is projected to hold a 32.5% share of the contraceptives market by 2036, underpinned by favorable regulatory developments and health insurance mandates ensuring widespread reimbursement coverage
- Asia Pacific is poised for the fastest growth during 2026–2036, fueled by government-sponsored family planning programs and rising disposable incomes
Segment Insights:
- The contraceptive devices sub-segment is anticipated to command a 65.5% share by 2036 in the contraceptives market, supported by increasing preference for long-acting and highly effective birth-control solutions and rising reproductive-health awareness
- The female sub-segment is projected to secure a considerable share by 2036, bolstered by the persistent unmet need for family-planning services among women and expanding access to modern contraceptive methods
Key Growth Trends:
- Rising awareness of contraception
- Expansion of contraceptive choices
Major Challenges:
- Side effects and patient compliance issues
- Socio-cultural and religious barriers
Key Players: Bayer AG (Germany),Organon & Co. (U.S.),CooperSurgical, Inc. (U.S.),Reckitt (UK),Pfizer Inc. (U.S.),Ansell Limited (Australia),Pregna International Ltd. (India).
Global Contraceptives Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2026 Market Size: USD 35.4 billion
- 2027 Market Size: USD 37.6 billion
- Projected Market Size: USD 65.7 billion by 2036
- Growth Forecasts: 6.4% CAGR (2027-2036)
Key Regional Dynamics:
- Largest Region: North America (32.5% Share by 2036)
- Fastest Growing Region: Asia Pacific
- Dominating Countries: United States, China, Japan, Germany, United Kingdom
- Emerging Countries: India, Brazil, Mexico, Indonesia, South Korea
Last updated on : 24 September, 2026
Contraceptives Market - Growth Drivers and Challenges
Growth Drivers
- Rising awareness of contraception: Rising awareness about contraception and family planning is encouraging individuals and couples to opt for birth-control methods. On the other hand, educational campaigns, healthcare counseling, social media, and community outreach are improving knowledge about available options, which are driving growth in the contraceptives market. National Institutes of Health (NIH) in June 2025 stated that in a study of 1,000 adults, contraceptive use was much higher in urban participants, at 74.0%, than in rural participants being 5.0%, whereas literacy and urban residence were strongly associated with contraceptive uptake. Besides, it also mentioned that urban participants more often used condoms and oral contraceptive pills, and sterilization was the predominant method in rural areas, at 50%.
- Expansion of contraceptive choices: The introduction of different types of contraceptive options is continuously stimulating market growth by addressing different consumer preferences and medical requirements. Modern choices include long-acting reversible contraceptives, injectable methods, implants, emergency contraceptives, oral pills, condoms, and intrauterine devices. In this context, ASKA Pharmaceutical in October 2025 obtained Japan’s marketing authorization to switch NORLEVO® (levonorgestrel) emergency contraceptive pill from prescription-only to over-the-counter use. Daiichi Sankyo Healthcare will manage distribution and sales, thus supporting appropriate and safe use of the emergency contraceptive.
Global Sheath Contraceptives Export Market 2024: Top Exporting Countries by Trade Value and Volume
|
Exporter |
Trade Value (1000 USD) |
Quantity (Kg) |
|
Thailand |
272,443.10 |
13,928,700 |
|
Malaysia |
74,445.00 |
- |
|
India |
68,935.63 |
5,412,290 |
|
China |
68,426.59 |
6,436,600 |
|
Japan |
33,138.01 |
699,379 |
|
European Union |
29,234.49 |
786,963 |
|
Germany |
22,270.16 |
478,355 |
|
Hungary |
17,115.14 |
126,375 |
|
Poland |
14,313.08 |
273,389 |
|
Spain |
12,916.74 |
386,615 |
|
U.S. |
12,003.58 |
476,807 |
|
Netherlands |
9,645.68 |
547,406 |
Source: WITS
Challenges
- Side effects and patient compliance issues: Consumer concerns regarding severe health side effects severely hamper the demand for existing hormonal contraceptive lines. Complications such as weight gain, mood fluctuations, nausea, decreased bone density, or minor cardiovascular risks are causing obstacles to adoption in the market across different nations. Apart from this, the rapid rise of unverified negative reviews and side-effect anecdotes on digital social media platforms fuels a negative effect among younger demographics. For daily oral pills, low patient compliance, such as forgetting consecutive doses, leads to unintended pregnancies and thus diminishes trust in the product's real-world efficacy.
- Socio-cultural and religious barriers: Socio-cultural resistance and deep-seated religious beliefs are considered to be primary obstacles restricting adoption and market expansion across several demographics. In most conservative societies or rural areas within developing regions, discussion of reproductive health is heavily stigmatized, which is suppressing active consumer demand. On the other hand, religious doctrines frequently forbid or openly discourage the utilization of modern birth control methods, which turns populations toward traditional, less effective alternatives. In addition, the existence of patriarchal family dynamics often strips women of autonomy regarding family planning decisions.
Contraceptives Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2026 |
|
Forecast Period |
2027-2036 |
|
CAGR |
6.4% |
|
Base Year Market Size (2026) |
USD 35.4 billion |
|
Forecast Year Market Size (2036) |
USD 65.7 billion |
|
Regional Scope |
|
Contraceptives Market Segmentation:
Product Segment Analysis
By the end of 2036, contraceptive devices sub-segment is anticipated to attain a dominating share of 65.5% during the forecast period. The sub-type’s dominance in the contraceptives market is supported by increasing preference for long-acting and highly effective birth-control solutions and rising awareness regarding reproductive health. On the other hand, growing availability of contraceptive devices such as intrauterine devices, implants, and vaginal rings is positioning the segment for extensive growth. In December 2024, Kenya received 31,300 Jadelle contraceptive implant sets, which were funded by the UK government in order to strengthen access to modern family-planning services and reduce contraceptive stock-outs. The supplies will help prevent approximately 60,073 unintended pregnancies, 1,014 maternal and child deaths, and 17,299 unsafe abortions, thus contributing to the segment’s expansion.
Gender Segment Analysis
On the basis of gender, female is forecasted to grow with a considerable share in the market by the end of 2036. The sub-segment’s growth is effectively propelled by the persistent unmet need for family-planning services among women, expanding access to modern contraceptive methods. In this context, UNFPA, in August 2023, donated intrauterine contraceptive devices to Jamaica’s National Family Planning Board to expand access to reliable, long-acting contraception. This initiative aimed to address teenage and unintended pregnancies by improving access to quality contraceptive options and strengthening reproductive-health education. Apart from this, it also supports UNFPA’s 2030 goals of eliminating unmet contraceptive needs, preventable maternal deaths, and harmful practices affecting women and girls.
Distribution Channel Segment Analysis
The retail pharmacies segment, which is a part of the distribution channel category, is expected to grow with a noteworthy share in the market from 2027 to 2036 due to increasing accessibility and convenience offered by community pharmacies. In addition, rising adoption of self-care approaches and the expanding role of pharmacists in providing contraceptive counselling and services also drive the segment’s growth. Apart from this, pharmacies are being recognized as an important access point for contraception, particularly in areas where access to clinics and other healthcare facilities is limited. In September 2024, WHO announced the launch of a free online course to train pharmacists and pharmacy staff in contraceptive counselling, prescribing, and follow-up care. This initiative mainly aims to strengthen pharmacy-based services and expand contraceptive access.
Our in-depth analysis of the market includes the following segments:
|
Segment |
Subsegments |
|
Product |
|
|
Gender |
|
|
Distribution Channel |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Contraceptives Market - Regional Analysis
North America Market Insights
The North America contraceptives market is forecasted to capture the largest share of 32.5% during the discussed timeframe. The region’s dominance is largely attributable to the extensive patient population of sexually active adolescents and career-oriented individuals seeking precise family planning. In addition, market growth in the region is largely propelled by favorable regulatory developments, along with health insurance mandates that ensure widespread reimbursement coverage. In this context, the U.S. Food & Drug Administration (FDA) in July 2023 accepted Opill (norgestrel) as the first daily oral contraceptive that will be sold without a prescription in the U.S. This nonprescription option is intended to reduce access barriers, thereby allowing consumers to obtain the pill directly from pharmacies, stores, and online retailers.
Percentage of U.S. Females Aged 15 - 49 Currently Using Contraception, 2022-2023
|
Category |
Group |
Currently Using Any Contraceptive Method (%) |
|
Overall |
Total |
54.3 |
|
Age |
15–19 years |
25.5 |
|
20–29 years |
52.4 |
|
|
30–39 years |
59.8 |
|
|
40–49 years |
64.9 |
|
|
Race & Hispanic Origin |
Black, non-Hispanic |
47.8 |
|
White, non-Hispanic |
58.7 |
|
|
Hispanic |
52.2 |
|
|
Education |
No high school diploma or GED |
55.9 |
|
High school diploma or GED |
56.9 |
|
|
Some college, no bachelor's degree |
61.3 |
|
|
Bachelor's degree or higher |
61 |
Source: CDC
A vast group of patient populations of reproductive-age individuals who are prioritizing lifestyle autonomy and family planning is an important factor driving growth in the U.S. contraceptives market. Dominant commercial trends are showcasing a migration toward digital healthcare, wherein subscription-based telehealth apps provide virtual consultations and discreet home delivery. In January 2024, KFF Organization stated that the U.S. government has supported family planning and reproductive health programs for nearly six decades, helping expand access to contraception, education, counseling, and related services. These efforts aim to reduce unintended pregnancies and maternal deaths while addressing barriers such as limited awareness, cost, gender inequality, and inadequate access to healthcare, thus denoting a positive opportunity for market expansion.
U.S. Government’s International Family Planning & Reproductive Health Funding: FY 2021 - FY 2025
Source: KFF
The Canada contraceptives market is gaining enhanced traction, which is due to the presence of a subsidized landscape and provincial policies that are offering universal, free prescription contraception coverage to youth and residents. In addition, strong federal initiatives in the country aimed at improving reproductive health equity in rural and Indigenous communities are driving extensive growth. Based on government data which was published in February 2024, Canada announced its plans to expand universal access to contraception by providing single-payer coverage for a wide range of contraceptive medicines and devices. Besides, it is helping reduce financial barriers and unintended pregnancies, and the initiative identifies that contraception costs affect young people, women, and lower-income individuals.
APAC Market Insights
The Asia Pacific market is anticipated to witness the fastest growth during the forecast period. The region’s progression in this sector is highly propelled by government-sponsored family planning programs and rising disposable incomes. Asia Pacific also benefits from intensive public health campaigns that are aimed at reducing unintended pregnancies and controlling the transmission of sexually transmitted infections. In this context, the Council on Foreign Relations in June 2023 stated that Japan has taken certain steps to improve access to emergency contraception by allowing selected pharmacies to sell these medicines without a prescription as part of a government trial. This initiative aims to help people obtain emergency contraception within the recommended 72-hour period while reducing barriers associated with clinic visits, cost, and limited healthcare access, thus improving uptake in the market.
The extensive patient population of young, urbanized consumers who utilize e-commerce platforms and digital pharmacies to cross traditional reproductive health stigmas is an important factor driving growth of China contraceptives market. In terms of recent trends and pricing dynamics, the commercial environment is navigating through profound structural shifts, with adoption rising for condoms, birth control pills, and devices. In August 2023, NIH disclosed that China’s changing fertility patterns have created a need to strengthen contraceptive services. This showcases greater emphasis on preventing unintended pregnancies, abortions, and sexually transmitted infections among people of reproductive age.
In India, the market is growing exponentially owing to the rising urbanization and strong government family planning initiatives. Market demand in the country is considered to be split between contraceptive drugs such as oral pills, injectables, and emergency contraceptives and contraceptive devices, including intrauterine devices, implants, and condoms. In December 2024, the Press Information Bureau (PIB) stated that India’s family planning programme has expanded access to a wide range of contraceptive methods, including condoms, oral pills, emergency contraception, IUCDs, sterilization, injectables and Centchroman. The government also implements initiatives such as Mission Parivar Vikas, sterilization compensation, ASHA-led home delivery of contraceptives, and awareness campaigns.
India’s Sheath Contraceptive Imports by Country in 2024
|
Country |
Trade Value (1000 USD) |
Quantity (Kg) |
|
Thailand |
2,346.76 |
52,843 |
|
China |
469.88 |
10,884 |
|
Malaysia |
285.44 |
32,150 |
|
Japan |
117.40 |
2,032 |
Source: WITS
Europe Market Insights
The Europe market is one of the most influential and largest, and it benefits from favorable government reimbursement policies and public acceptance across nations. Growth in this regional market is primarily propelled by the integration of telehealth services and direct-to-consumer digital health apps that streamline remote prescription and delivery. European Parliamentary Forum (EPF) in February 2025 stated that there is a growing use of AI and fertility-tracking apps in reproductive health, whereas there are rising concerns about privacy, misinformation, reliability, and algorithmic bias. In this context, EPF calls for wider access to affordable contraception, free counselling, accurate health information, and responsible regulation of emerging reproductive technologies, thus indicating an optimistic market opportunity.
The advanced healthcare infrastructure and a strong statutory health insurance system are two main factors driving the growth of market in Germany. This environment has accelerated the adoption of copper intrauterine devices, cycle-tracking fertility apps certified as medical products, and premium barrier methods. The government supports extensive R&D to explore newer growth opportunities in this sector. In February 2026, CTI Exchange stated that Germany is investing USD 14.05 million from 2026 to 2029 in four research projects focused on developing safer, non-hormonal contraceptive options, including innovative approaches to male contraception. These projects will explore sperm-specific treatments, reversible methods that affect sperm transport, and improved digital cycle-tracking and fertility-detection technologies.
The UK contraceptives market is gaining strong exposure, which is facilitated by healthcare shifts that are primarily led by the expansion of the NHS. At the same time, demand within this market is highly propelled by utilization of dual-protection methods such as condoms due to persistent public health emphasis on managing STI rates, along with a strong trend in long-acting reversible contraceptives such as implants and intrauterine devices. In November 2023, government data disclosed that women in England can get contraceptive pills directly from participating pharmacies without first visiting a GP, and this made contraception more accessible. It also mentioned that pharmacists provide confidential consultations; they can supply both combined and progestogen-only pills free of charge, and checks such as blood pressure and BMI are required for combined contraception.
Key Contraceptives Market Players:
- Bayer AG (Germany)
- Organon & Co. (U.S.)
- CooperSurgical, Inc. (U.S.)
- Reckitt (UK)
- Pfizer Inc. (U.S.)
- Ansell Limited (Australia)
- Pregna International Ltd. (India)
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pregna International Ltd. is considered to be a leading manufacturer of intrauterine contraceptive devices in India which is offering copper IUDs, hormonal contraceptives, and tubal rings. The company states that its products have reached over 100 million women across 140 countries.
- Bayer AG is also a prominent player in this sector, which offers a range of hormonal contraceptive methods, including oral contraceptives, intrauterine systems, patches, vaginal rings, implants, and injectables. The firm is highly focused on providing several contraceptive options based on individual needs.
- Organon & Co. primarily focuses on women's health, and its portfolio covers fertility and contraception, maternal health, and vaginal health. Apart from this, the company operates across more than 140 markets globally.
- CooperSurgical, Inc. offers Paragard®, which is an intrauterine copper contraceptive. The company operates within the fertility and medical devices sectors and is headquartered in Trumbull, Connecticut, U.S.
- Reckitt manufactures and markets Durex®, which it describes as the world's No. 1 condom brand. Also, Durex has more than 90 years of experience, and it extensively focuses on condom innovation, intimate wellness, and sexual security.
Here is a list of key players operating in the global market:
The global contraceptives market includes leading manufacturers such as Bayer, Organon, CooperSurgical, and Reckitt, and they are maintaining strong positions through broad product portfolios and established geographic presence. Competition in this sector spans hormonal contraceptives, intrauterine devices, implants, and condoms, whereas differentiation is driven by product efficacy, safety, innovation, brand strength, and clinical evidence. In this context, Viatris in July 2026 received U.S. FDA approval for Gwyn Lo™, which is a once-weekly combined hormonal contraceptive patch, and it delivers norelgestromin 220 mcg/day and ethinyl estradiol 20 mcg/day. The company also mentioned that phase 3 results showed contraceptive efficacy and strong patch adhesion.
Corporate Landscape of the Market:
Recent Developments
- In July 2026, Bayer secured a total of USD 3.5 billion from Apollo to strengthen its capital structure through a minority stake in its long-acting reversible contraceptives business. Bayer will retain majority ownership and full operational control, with no changes planned to the business’s strategy or activities.
- In January 2026, Organon announced that the U.S. FDA approved extending NEXPLANON’s contraceptive use from three to five years, and no pregnancies were reported during years four and five of the clinical trial.
- Report ID: 4635
- Published Date: Sep 24, 2026
- Report Format: PDF, PPT
- Explore a preview of key market trends and insights
- Review sample data tables and segment breakdowns
- Experience the quality of our visual data representations
- Evaluate our report structure and research methodology
- Get a glimpse of competitive landscape analysis
- Understand how regional forecasts are presented
- Assess the depth of company profiling and benchmarking
- Preview how actionable insights can support your strategy
Explore real data and analysis
Frequently Asked Questions (FAQ)
About this Report
Connect with our Expert
Report, 2027-2036
Copyright @ 2026 Research Nester. All Rights Reserved.
